Hospital

Measles cases surge in the US, prompting quarantine measures in South Carolina schools and raising urgent vaccination concerns amid declining rates.

Prateek Bhatia discusses optimizing infusion operations through technology, data analytics, and patient journey understanding at the ASHP Midyear Meeting.

Host Craig Beavers sits down with Marc Baines, cofounder and executive director of the HeartLife Foundation, to explore heart failure care through the lens of lived experience.

The approval is supported by findings from the phase 3 DESTINY-Breast09 trial.

Pharmacists play a vital role in modern clinical trials, enhancing patient safety and trial efficiency through drug management and protocol development.

Lerodalcibep, a new PCSK9 inhibitor, offers a convenient monthly injection to effectively lower LDL cholesterol in patients with hypercholesterolemia.

Research reveals that isatuximab on-body injector shows consistent safety and efficacy across various body weight groups in multiple myeloma treatment.

SABCS 2025 showcases breakthroughs in breast cancer therapy, emphasizing novel therapies and precision medicine to enhance patient outcomes.

Pivotal FDA approvals in breast cancer treatment focused on precision medicine and innovative therapies in 2025.

Discover how antibody drug conjugates (ADCs) are transforming treatment for HER2-positive breast cancer with brain metastases at SABCS 2025.

After 2 initial doses, inebilizumab is administered with only 2 doses a year.

As the new chair of the Advisory Committee on Immunization Practices (ACIP) signals interest in revisiting childhood and adolescent vaccine schedules, immunologist Morgan McSweeney, PhD, stresses that any changes must be anchored in decades of rigorous safety and efficacy data.

Experts explore the evolving role of HER2- and TROP2-targeted therapies in breast cancer treatment at SABCS 2025, highlighting ADC advancements.

FDA approves gepotidacin as a new oral treatment for uncomplicated gonorrhea, expanding options against resistant sexually transmitted infections.

Latest findings presented at SABCS 2025 support trastuzumab deruxtecan's effectiveness and safety in treating HER2-positive breast cancer.

Diana Isaacs, PharmD, highlights evolving criteria for insulin pump therapy in type 2 diabetes.

Ginger Thorpe discusses how in-house specialty pharmacy models enhance patient care, streamline communication, and boost health system revenue amid rising demand.

Tucatinib enhances first-line maintenance therapy for HER2-positive metastatic breast cancer, improving progression-free survival and safety outcomes, as shown in the HER2CLIMB-05 trial.

Cell-cycle–focused CDK inhibitors offer new options for HR+/HER2– metastatic breast cancer after CDK4/6 resistance.

Allegheny General Hospital enhances pharmacy operations through centralized, robotics-enabled IV compounding, boosting efficiency and patient care.

Prescriber incentives boost nicotine replacement therapy prescribing and enhance patient access to smoking cessation support in health care settings.

The FDA approved etuvetidigene autotemcel, the first gene therapy for Wiskott-Aldrich syndrome, transforming treatment options for affected patients.

Oral SERDs and combination therapies are redefining post-CDK4/6 treatment in HR+/HER2– metastatic breast cancer.

Pharmacy leaders navigate complex compliance challenges, budget constraints, and evolving technology to enhance safety and efficiency in compounding practices.

IV compounding robotics enhance safety, reduce drug shortages, and improve efficiency in hospital pharmacies, driving a shift towards automation.

Exploratory analysis shows 1 in 4 patients maintain a long-term response to ribociclib.

Pharmacists leverage sodium-glucose cotransporter 2 (SGLT2) inhibitors to improve interconnected cardiovascular-kidney-metabolic (CKM) syndrome outcomes through holistic, patient-centered care.